190 related articles for article (PubMed ID: 26506236)
1. The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.
Knoll M; Macher-Goeppinger S; Kopitz J; Duensing S; Pahernik S; Hohenfellner M; Schirmacher P; Roth W
Oncotarget; 2016 Jan; 7(1):418-32. PubMed ID: 26506236
[TBL] [Abstract][Full Text] [Related]
2. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Nakai Y; Miyake M; Morizawa Y; Hori S; Tatsumi Y; Anai S; Onishi S; Tanaka N; Fujimoto K
Oncol Rep; 2017 Jan; 37(1):227-234. PubMed ID: 27840968
[TBL] [Abstract][Full Text] [Related]
3. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
Chen B; Tan Z; Gao J; Wu W; Liu L; Jin W; Cao Y; Zhao S; Zhang W; Qiu Z; Liu D; Mo X; Li W
J Exp Clin Cancer Res; 2015 Oct; 34():126. PubMed ID: 26490682
[TBL] [Abstract][Full Text] [Related]
5. DRAM1 regulates autophagy and cell proliferation via inhibition of the phosphoinositide 3-kinase-Akt-mTOR-ribosomal protein S6 pathway.
Lu T; Zhu Z; Wu J; She H; Han R; Xu H; Qin ZH
Cell Commun Signal; 2019 Mar; 17(1):28. PubMed ID: 30902093
[TBL] [Abstract][Full Text] [Related]
6. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
7. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma.
Qu Y; Zhao R; Wang H; Chang K; Yang X; Zhou X; Dai B; Zhu Y; Shi G; Zhang H; Ye D
Sci Rep; 2016 Mar; 6():23594. PubMed ID: 27026382
[TBL] [Abstract][Full Text] [Related]
9. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
[TBL] [Abstract][Full Text] [Related]
10. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
11. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.
Li X; Hou G; Zhu Z; Yan F; Wang F; Wei D; Zheng Y; Yuan J; Zheng W; Zhang G; Meng P; Guo Y; Li X; Yao L; Shen L; Yuan J
Invest New Drugs; 2020 Aug; 38(4):956-966. PubMed ID: 31463638
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
[TBL] [Abstract][Full Text] [Related]
13. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.
Zou Y; Wang J; Leng X; Huang J; Xue W; Zhang J; Huang Y
Oncotarget; 2017 Mar; 8(13):20825-20833. PubMed ID: 28212559
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer.
Yang X; Xu L; Yang YE; Xiong C; Yu J; Wang Y; Lin Y
J Ovarian Res; 2020 Aug; 13(1):100. PubMed ID: 32862831
[TBL] [Abstract][Full Text] [Related]
15. Ribosomal s6 protein kinase 4: a prognostic factor for renal cell carcinoma.
Fan L; Li P; Yin Z; Fu G; Liao DJ; Liu Y; Zhu J; Zhang Y; Wang L; Yan Q; Guo Y; Shao C; Huang G; Wang Z
Br J Cancer; 2013 Sep; 109(5):1137-46. PubMed ID: 23942078
[TBL] [Abstract][Full Text] [Related]
16. Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition.
Abdel-Kahaar E; Kabakchiev M; Hartmann B; Wieland E; Shipkova M
Clin Biochem; 2016 Oct; 49(15):1181-1187. PubMed ID: 27372285
[TBL] [Abstract][Full Text] [Related]
17. Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
Semeniuk-Wojtaś A; Stec R; Szczylik C
Urol Oncol; 2016 May; 34(5):215-20. PubMed ID: 26850779
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas.
Chaux A; Albadine R; Schultz L; Hicks J; Carducci MA; Argani P; Allaf M; Netto GJ
Hum Pathol; 2013 Oct; 44(10):2323-30. PubMed ID: 23953228
[TBL] [Abstract][Full Text] [Related]
19. Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma.
Khella HW; Scorilas A; Mozes R; Mirham L; Lianidou E; Krylov SN; Lee JY; Ordon M; Stewart R; Jewett MA; Yousef GM
Am J Pathol; 2015 Mar; 185(3):693-703. PubMed ID: 25572155
[TBL] [Abstract][Full Text] [Related]
20. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.
Haddad AQ; Kapur P; Singla N; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Sagalowsky A; Lotan Y; Margulis V
Cancer; 2015 Jan; 121(1):43-50. PubMed ID: 25186283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
